A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods

Clinical Cancer Research

Volumn 11, Issue 15, 2005, Pages 5440-5443

  Zlobec, Inti ^a   Steele, Russell ^a   Nigam, Nilima ^a   Compton, Carolyn C ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; VASCULOTROPIN;

ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; BRACHYTHERAPY; CLASSIFICATION; CLASSIFICATION AND REGRESSION TREE METHOD; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE; RECTUM TUMOR; TUMOR BIOPSY; VALIDATION PROCESS;

APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BIOPSY; BRACHYTHERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; OXYGEN; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RECTAL NEOPLASMS; REGRESSION ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23044492303     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2587     Document Type: Article

References (46)

1. Swedish Rectal Cancer Trial. Improved survival with pre-operative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-7.
2. Swedish Rectal Cancer Trial. Local recurrence rate in a randomized multicentre trial to pre-operative radiotherapy compared with operation alone in resectable rectal carcinoma. Eur J Surg 1996;162:397-402.
3. Glimelius B, Gronberg H, Jarhult J, et al. A systematic review of radiation therapy effects in rectal cancer. Acta Oncol 2003;42:476-92.
4. Sauer R, Fietkau C, Wittekind C, et al. Pre-operative versus post-operative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
5. Vuong T, Belliveau P, Michel R, et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum 2002;45:1486-95.
6. Gerard J-P, Chapet O, Nemoz C, et al. Improved sphincter preservation in low rectal cancer with high-dose pre-operative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol 2004;22:2404-9.
7. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:928-42.
8. Dahm-Daphi J. p53: biology and role for cellular radiosensitivity. Strahlenther Onkol 2000;176:278-85.
9. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev 2004;23:237-57.
10. McKay J, Douglas JJ, Ross VG, et al. Analysis of key cell-cycle checkpoints in colorectal tumors. J Pathol 2002;196:386-93.
11. Qiu H, Sirivongs P, Rothenberger M, et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000;43:451-9.
12. Charara M, Edmonston TB, Burkholder S, et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 2004;24:3161-7.
13. Reerink O, Karrenbeld A, Plukker JT, et al. Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res 2004;24:1217-21.
14. Galizia G, Lieto E, Ferraraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004;10:3490-9.
15. Spitz F, Giacco G, Hess K, et al. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 1997;3:1685-90.
16. Kandioler D, Zwrtek R, Ludwig C, et al. TP53 genotype but not p53 immunohistochemistry result predicts response to pre-operative short-term radiotherapy in rectal cancer. Ann Surg 2002;235:493-8.
17. Nehls O, Klump B, Holzmann K, et al. Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 1999;85:2541-8.
18. Okonkwo A, Musunuri S, Talamonti M, et al. Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep 2001;8:497-500.
19. Kim NK, Park JK, Lee KY, et al. p53, BCL-2 and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 2001;8:418-24.
20. Rebischung C, Gerard JP, Gayet J, et al. Prognostic value of p53 mutations in rectal carcinoma. Int J Cancer 2002;100:131-5.
21. Kondo Y, Arii S, Furutani M, et al. Implication of vascular endothelial growth factor and p53 status for angiogenesis in non-invasive colorectal carcinoma. Cancer 2000;88:1820-7.
22. Kang S-M, Maeda K, Onoda N, et al. Combined analysis of p53 and vascular endothelial growth factor in CRC for determination of tumor vascularity and liver metastasis. Int J Cancer 1997;74:502-7.
23. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
24. Nozue M, Isaka N, Fukao K. Over-expression of vascular endothelial growth factors after pre-operative radiation therapy for rectal cancer. Oncol Rep 2001;8:1247-9.
25. Wong MP, Cheung N, Yuen ST, et al. Vascular endothelial GF is up-regulated in the early pre-malignant stage of colorectal tumor progression. Int J Cancer 1999;81:845-50.
26. Willett C, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat Med 2004;10:145-7.
27. Ferrara N. Vascular Endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
28. Gastman BR. Apoptosis and its clinical impact. Head Neck 2001;23:409-25.
29. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280-3.
30. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004;9:691-704.
31. Brieman L, Friedman J, Olshen R, Stone C. Classification and regression trees. Belmont (CA): Wadsworth, Inc.; 1984.
32. Ripley B. Pattern recognition for neural networks. Oxford, UK: Cambridge University Press, 1996.
33. McKinney WP, Young MJ, Hartz A, Lee MB. The inexact use of Fisher's Exact Test in six major medical journals. JAMA 1989;261:3430-3.
34. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001;93:208-13.
35. Hyen Baek J, Jang J-E, Kang C-M, et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000;19:4621-31.
36. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000;26:657-62.
37. Broll R, Erdmann H, Duchrow M, et al. Vascular endothelial growth factor (VEGF)-a valuable serum tumor marker in patients with colorectal cancer? Eur J Surg Oncol 2001;27:37-42.
38. De Vita F, Orditura M, Lieto E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004;100:270-8.
39. Pidgeon GP, Barr MP, Harmey JH, et al. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001;85:273-8.
40. Hwang TS, Han HY, Choi HY, et al. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol 2003;18:690-700.
41. Katsumata K, Sumi T, Tomioka H, et al. Induction of apoptosis by p53, bax, bcl-2, and p21 expressed in colorectal cancer. Int J Clin Oncol 2003;8:352-6.
42. Brown G, Davies S, Bourne MW, et al. Effectiveness of pre-operative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer 2004;91:23-9.
43. Zirbes TK, Baldus SE, Moenig SP, et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000;89:14-8.
44. Viale G, Pellegrini C, Mazzarol G, et al. P21 waf1/cip1 expression in colorectal cancer correlates with advanced disease stage and p53 mutations. J Pathol 1999;187:302-7.
45. Cascinu S, Graziano F, Catalano V, et al. An analysis of p53, BAX, and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumor recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br J Cancer 2002;86:774-9.
46. Scopa CD, Vagianos C, Kardamakis D, et al. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 2001;9:329-34.